Also, a recent publication showed that although APOE ɛ4 carriers had more severe amyloid pathology, the total tau burden and the global cognitive impairment index did not differ from APOE ɛ4 noncarriers in 121 autopsy-confirmed PSP patients35. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.